Last update Nov. 5, 2024
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Flunisolide in other languages or writings:
Flunisolide belongs to these groups or families:
Main tradenames from several countries containing Flunisolide in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 21 | % |
Molecular weight | 435 | daltons |
Protein Binding | 40 | % |
VD | 1.8 | l/Kg |
pKa | 13.7 | - |
Tmax | 0.5 | hours |
T½ | 1.8 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Flunisolide is an inhaled corticosteroid used as prophylactic therapy in the maintenance treatment of asthma and atopic rhinitis.
At the date of last update we found no published data in relation to breastfeeding.
Its pharmacokinetic characteristics (low systemic absorption, moderately high molecular weight and high volume of distribution) make passage into breast milk very unlikely.
Its low oral bioavailability makes it difficult to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period in which there may be greater intestinal permeability.
Several medical societies and expert authors consider Flunisolide and, in general, corticosteroids, topical, systemic or inhaled, to be safe and/or probably compatible with breastfeeding. (Hale, LactMed, Middleton 2020, Briggs 2015, Schaefer 2015, National Asthma 2004)